GALAPAGOS NV |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.58 EUR | +0.08% |
|
-2.21% | -28.14% |
Presenter SpeechSofie Van Gijsel (Executives)Welcome all to the Galapagos Capital Markets Day ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
2024-04-30
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.56
EUR
Average target price
38.43
EUR
Spread / Average Target
+44.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.14% | 1.87B | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.81% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- Transcript : Galapagos NV, Q3 2022 Earnings Call, Nov 04, 2022
